Oral Small-Molecule GLP-1 RAs Offer Enhanced Access and Adherence for Cardiometabolic Conditions
Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine.
Abstract
Oral small-molecule GLP-1 receptor agonists, including orforglipron, promise improved accessibility and adherence for type 2 diabetes and obesity management.
